425: Quanterix and Akoya Biosciences Amend Merger Agreement, Lowering Share Issuance and Increasing Cash Component

Quanterix and Akoya Biosciences have amended their merger agreement, reducing the number of Quanterix shares to be issued and increasing the cash consideration for Akoya shareholders.

Summary

• Quanterix and Akoya Biosciences have amended their merger agreement, with Quanterix issuing approximately 7.76 million shares and paying $20 million in cash to Akoya shareholders.
• Each Akoya share will receive $0.38 in cash and 0.1461 shares of Quanterix common stock.
• Quanterix shareholders will own approximately 84% of the combined company, while Akoya shareholders will own approximately 16%.
• The combined company is expected to have approximately $220 million in annual revenue and $155 million in cash with no debt at close, with projected cash flow breakeven in 2026.
• The transaction is expected to close in the second quarter of 2025, pending Akoya shareholder approval and customary closing conditions.
• Akoya shareholders holding more than 50% of Akoya's common stock have agreed to vote in favor of the merger on the amended terms.
• Quanterix will no longer hold its previously announced special meeting of shareholders.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the amended merger agreement, highlighting the strategic benefits and financial improvements for Quanterix stockholders. While acknowledging market volatility, the overall tone is optimistic about the combined company's future prospects.

Positives

• The amended transaction provides Quanterix stockholders with greater ownership and a larger percentage of the future profits and value of the combined company.
• The combined company is expected to have a strong balance sheet with ~$155M in cash expected at time of closing.
• The transaction accelerates Quanterixs path to cash flow breakeven and supports the Companys goal of continuing to deliver strong double digit annual organic revenue growth.
• The combination is expected to generate $40 million in annual cost savings by the end of 2026, with $20 million expected to be realized within the first year following closing.

Negatives

• Akoya shareholders will have reduced ownership in the combined company, down from ~29% to ~16%.

Risks

• The transaction is subject to Akoya shareholder approval and customary closing conditions, which may not be satisfied.
• The anticipated benefits and synergies of the merger may not be realized when expected or at all.
• The integration of the two companies may present challenges and problems.
• The merger may be more expensive to complete than anticipated.
• The transaction could divert management's attention from ongoing business operations and opportunities.
• Potential adverse reactions or changes to business or employee relationships could occur.
• Changes in Quanterix's share price before the closing of the merger could affect the value of the transaction.
• The potential dilutive effect of shares of Quanterix common stock to be issued in the merger poses a risk.
• Akoya's ability to repay any Convertible Notes could be impacted.

Future Outlook

The combined company expects strong organic revenue growth by 2026 and anticipates reaching cash flow breakeven in 2026.

Management Comments

• Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said, 'The strategic merits of the transaction remain strong even as the market has been focused on academic funding and tariff concerns. In light of recent volatility, we re-engaged with Akoya to revise the terms of the agreement. The combined company will provide a significant value creation opportunity for shareholders.'
• Brian McKelligon, Chief Executive Officer of Akoya, said, 'We remain excited to combine with Quanterix and believe this partnership offers compelling value for Akoya shareholders. We look forward to closing the transaction and leveraging our collective scale to drive synergies across our organizations and customers, expediting our path to profitability.'

Industry Context

The announcement reflects a trend of consolidation in the life sciences tools industry, with companies seeking to expand their technology portfolios and market reach. The combination aims to create a more durable business in a dynamic industry environment.

Comparison to Industry Standards

• The implied transaction multiple for Akoya is the lowest among comparable life sciences transactions over the last few years.
• The combined company is expected to have a higher revenue growth trajectory and gross margin profile compared to other performance peers such as 10xGenomics, Cytek Biosciences, Illumina, Nautilus Biotechnology, Pacific Biosciences of California, Quantum Si, Seer and Standard BioTools.
• Scaled life sciences tools companies are generally rewarded with higher valuation multiples and have historically delivered superior returns compared to smaller companies.

Stakeholder Impact

• Quanterix stockholders will have a larger ownership stake in the combined company.
• Akoya stockholders will receive cash and Quanterix shares as consideration for their shares.
• Employees of both companies may experience changes as a result of the integration.
• Customers of both companies are expected to benefit from a broader range of products and services.

Next Steps

• Akoya shareholders need to approve the amended merger agreement.
• The transaction is subject to customary closing conditions.
• Quanterix will file a post-effective amendment to its registration statement with the SEC.
• Akoya will mail a definitive copy of the Proxy Statement/Prospectus to its stockholders.

Key Dates

Keywords

merger, akoya biosciences, quanterix, amended agreement, share issuance, cash consideration, spatial biology, biomarker detection, acquisition